Wombat Capital
Wombat Capital describes itself as a cross-border investment banking and strategic advisory firm serving pharma outsourcing, medical devices, and diagnostics. Its affiliated structure includes a U.S. broker-dealer and a French M&A adviser.
What stands out about Wombat Capital
Wombat Capital publicly states that it provides cross-border investment banking, strategic advisory, M&A advisory, and private placements of securities to institutional investors. Its public materials identify sector coverage in pharma outsourcing, medical devices, and diagnostics, while the current official homepage does not state minimum client-size or transaction-size criteria.[1][2][3][4][6][8]
What does Wombat Capital do?
Wombat Capital describes itself as a cross-border investment banking and strategic advisory firm serving the pharma outsourcing, medical devices, and diagnostics industries.
The WOMBAT CAPITAL trade name covers Wombat Capital Ltd., Wombat Capital Markets LLC, a U.S. broker-dealer registered with FINRA, and Wombat Capital Markets SAS, a French M&A adviser.[1][2]
Publicly stated services include investment banking, strategic advisory, mergers and acquisitions advisory, and private placements of securities. Wombat Capital Markets LLC states that it provides financial advisory services in connection with mergers, acquisitions, and private placements.
The Form CRS states that the LLC offers private placements to institutional investors and conducts M&A advisory work with institutional customers. In M&A advisory work, compensation may include a success fee when an engagement is consummated, as well as retainer or advisory fees paid by the issuer.[3][4]
Owners comparing advisory firms can also review Auxo’s M&A advisor vs. business broker vs. investment bank comparison, advisor-selection guide, and sell-side advisor evaluation framework.
What should a business owner evaluate before hiring Wombat Capital?
Owners evaluating Wombat Capital can clarify which affiliated legal entity would sign an engagement and receive fees, particularly because the platform includes a U.S. broker-dealer and a French M&A adviser. The documented service model also makes it appropriate to confirm whether the proposed work would be M&A advisory, broker-dealer-related private-placement activity, or another advisory arrangement.
The firm’s stated sector focus and cross-border positioning can be assessed against a company’s activities and geographic objectives. Because the current official homepage does not state client-size criteria, an owner should obtain the firm’s applicable revenue, EBITDA, enterprise-value, or transaction-size parameters directly. Fee mechanics, conflicts, confidentiality protections, buyer coverage, and comparable team experience should also be addressed in the engagement discussion.[1][2][3][4]
Which Wombat legal entity would sign the engagement and receive fees
What revenue, EBITDA, enterprise-value, or transaction-size ranges does the firm actively cover
What size transactions and clients does Wombat Capital focus on?
The firm’s publicly stated industry focus is pharma outsourcing, medical devices, and diagnostics.[1]
- Wombat Capital submitted the PharmaCore acquired by Cambrex transaction in the healthcare/pharma category of the 2017 ACG New York Champion’s Awards.
- Wombat Capital was listed among the advisers for the acquisition of J-STAR Research Inc. by Porton USA in 2018 International M&A Awards materials.
- Wombat Capital Markets was listed as adviser for the acquisition of Snapdragon Chemistry by Cambrex in the 2023 M&A Advisor Awards finalist materials.
- TEAM Technologies announced its acquisition of TAG3 Engineering on September 17, 2025; the announcement states that Wombat Capital advised TAG3 on the sale.
Wombat Capital publicly identifies mergers and acquisitions advisory and private placements of securities to institutional investors as areas of activity. Its public transaction examples include healthcare, pharmaceutical, life-science, and medical-device-related transactions.[3][4][6][7][8][9]
What does Wombat Capital publicly disclose about fees, process and engagement terms?
The current official homepage does not state minimum revenue, EBITDA, enterprise-value, transaction-value, employee-count, or other client-size criteria.
The cited Form CRS does not publish a universal M&A success-fee percentage, minimum fee, tail period, or termination schedule. It states only that success fees and possible retainer or advisory fees may apply and vary by issuer or engagement.
The cited 2023 M&A Advisor finalist list identifies the Snapdragon Chemistry/Cambrex transaction and Wombat Capital Markets but does not disclose Wombat’s fee, mandate scope, consideration terms, or a complete transaction chronology. The cited 2017 ACG award document likewise does not disclose the firm’s fee, mandate scope, or transaction consideration for the PharmaCore/Cambrex transaction.
The official legal page describes the affiliated-entity structure but does not state a consolidated employee count, revenue figure, assets under management, or other firm-size metric.[1][2][4][6][8]
Wombat Capital Markets LLC is identified as a New York limited liability company wholly owned by Wombat Worldwide Group LLC. It is described as a broker-dealer registered with the SEC and operating under a FINRA membership agreement.
FINRA’s firm report identifies Wombat Capital Markets LLC as CRD #162699 and SEC #8-69059 and states that it is registered with the SEC, one self-regulatory organization, and 29 U.S. states and territories. The broader WOMBAT CAPITAL structure also includes Wombat Capital Ltd. and Wombat Capital Markets SAS, identified on the legal page as a French M&A adviser.[2][3][5]
The official legal page states that completed-engagement tombstones are posted selectively based on relevance and significance, subject to confidentiality concerns and client approval.[2]
Questions to ask before hiring Wombat Capital
Which Wombat legal entity would sign the engagement and receive fees?
What revenue, EBITDA, enterprise-value, or transaction-size ranges does the firm actively cover?
Which recent comparable transactions were led by the proposed team?
What is the proposed retainer, success-fee basis, expense policy, tail period, and termination schedule?
How are conflicts handled where the firm also conducts private placements or represents institutional investors?
Which strategic buyers, private-equity sponsors, or cross-border buyers would be approached?
Sources & research notes
- Official website / firm overview
- Structure / regulatory context
- SEC filing / regulatory record
- Services / capabilities
- FINRA regulatory record
- Transaction / portfolio evidence
- Transaction / portfolio evidence
- Transaction / portfolio evidence
- Transaction / portfolio evidence
How this profile was researched
Auxo profiles are prepared from publicly available primary and authoritative sources and reviewed for entity identity, factual support and disclosure consistency. When a fact cannot be supported by the reviewed public record, the profile identifies it as something to confirm directly rather than inferring it.
Independent research profile
This profile was prepared by Auxo Capital Advisors from publicly available information believed to be reliable and is provided solely for informational and educational purposes. It is not an endorsement, recommendation, ranking, solicitation, or representation regarding the profiled firm, its services, qualifications, transaction experience, regulatory status, financial condition, or suitability for any particular person, company, transaction, or investment.
Information obtained from third-party and public sources may be incomplete, inaccurate, outdated, or subject to change, and Auxo Capital Advisors makes no representation or warranty, express or implied, as to its accuracy, completeness, or timeliness. Readers should conduct their own independent diligence and consult appropriate professional advisers before engaging any advisor, intermediary, investor, lender, acquirer, or other transaction counterparty.
Broker-dealer and securities disclosure
Auxo Capital Advisors is an affiliate of Weild & Co., Member FINRA | SIPC. Securities-related activities and securities transactions are conducted through Weild & Co.
Nothing contained on this page constitutes an offer to sell, an offer to purchase, or a solicitation of an offer to buy or sell any security, investment product, or financial instrument. Nothing on this page constitutes investment advice, a recommendation regarding any security, or a recommendation to enter into any transaction with the profiled firm or any other party.
Any securities transaction, capital-raising engagement, investment-banking engagement, or other securities-related activity involving Auxo Capital Advisors or Weild & Co. is subject to applicable regulatory requirements, internal review and approval, suitability and other applicable diligence requirements, and the terms of a separate written engagement or transaction agreement, as applicable.
Inclusion of a third-party firm in this directory does not imply affiliation with, sponsorship by, endorsement by, or any other relationship with Auxo Capital Advisors or Weild & Co. unless expressly stated otherwise.